|
Published by: BCC Research
Published: Oct. 1, 2002 - 197 Pages
Table of Contents
Introduction
- Objectives And Goals Of Study
- Contribution Of The Study And For Whom
- Study Scope And Format
- Methodology
- Information Sources
- Related Bcc Publications
- Bcc On-Line Services
Summary
Overview
- Definitions
- The Importance Of Antibody Drugs And Diagnostics
- Major Technical Issues
- The Hama Problem And Its Resolution
- Phage Display And Polysome Display
- Antibody Conjugates
- Camouflaged Antibodies
- Fully Human Antibodies
- Synthetic Antibodies
- Progenitor Stem Cells
- Building A Better Mouse
- ...And Goat
- ...And Chicken
- Using Monoclonal Antibodies As Carriers For Cytotoxic Drugs
- Advantages Of Monoclonal Antibody Drugs
- New Directions In Antibody Research
- Challenges In Meeting Production Demands
- Why Do Monoclonal Antibody Products Have So Many Applications And Polyclonal Antibody Products Do Not?
- Valuation Of Antibody Product Sales
Technology
- Antibody Classes
- Antibody Forms In Products
- Antiserums
- Single-Chain Antibodies
- Abtides
- Bispecific Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- The Special Case Of Enbrel
- Gene Therapy
Products
- The Market For Monoclonal And Polyclonal Antibody Drugs
- Therapeutic Monoclonal Antibody Products
- The Market For Therapeutic Monoclonal Antibodies
- Marketed Products
- Campath®/Mabcampath
- Herceptin®
- Mylotarg®
- Orthoclone Okt3®
- Panorex®
- Remicade®
- Reopro®
- Rituxan/Mabthera®
- Simulect®
- Synagis®
- Zenapax®
- Zevalin™
- Products In Development
- Abx-Cbl
- Antegren®
- Avastin™
- Bec2
- Bexxar®
- Cat-152
- Cdp 870
- D2e7
- Erbitux™
- Felvizumab
- Hnk20
- Humax-Cd4
- Humicade™
- Ing-1
- Lymphocide™
- Mabthera®
- Mdx-210
- Oncolym®
- Ovarex®
- Panorex®
- Pemtumomab
- Protovir™
- Ragavirumab
- Remicade®
- Rituxan®
- Segard
- Simulect®
- Synagis®
- Xanelim™
- Xolair™
- Zamyl®
- Therapeutic Polyclonal Antibody Products
- Marketed Products
- Anti-Thymocyte Globulin
- Atgam®
- Thymoglobulin®
- Crofab®
- Cytogam®
- Digitab®
- Diphtheria Antitoxin
- Hepatitis B Immune Globulin
- Immunoglobulins
- Intramuscular Products
- Intravenous Products
- Rabies Immune Globulin
- Respigam®
- Rho(D) Immune Globulin
- Tetanus Immune Globulin
- Varicella-Zoster Immune Globulin
- Vipertab®
- Products In Development
- Cytotab®
- Thymoglobulin®
- In Vivo Diagnostic Antibody Products
- Marketed Products
- Cea-Scan®
- Leukoscan®
- Oncoscint®
- Prostascint®
- Afp-Scan
- Cea-Scan
- Leukoscan
- Lymphoscan
- Prostascint
- Tru-Scint Ad
- Tru-Scint Ag
Applications
- Leading Therapeutic Indications Of Approved Monoclonal Therapeutic Antibody Products
- Allergic Rhinitis And Asthma
- Antibodies In Development For The Treatment Of Allergic Rhinitis And Asthma
- Cancer
- U.S. Cancer Statistics
- Breast Cancer
- Colorectal Cancer
- Head And Neck Cancer
- Kidney Cancer
- Leukemias
- Liver Cancer
- Lung Cancer
- Malignant Melanoma
- Nonhodgkin’s Lymphoma
- Ovarian Cancer
- Osteosarcoma
- Pancreatic Cancer
- Prostate Cancer
- Stomach Cancer
- Antibodies In Development For The Treatment Of Cancer
- Cardiovascular Diseases
- Percutaneous Transluminal Coronary Angioplasty
- Antibodies In Development For The Treatment Of Cardiovascular Diseases
- Infectious Diseases
- Cytomegalovirus Infection
- Hepatitis
- Respiratory Syncytial Virus Infection
- Antibodies In Development For The Treatment Of Infectious Diseases
- Organ Transplantation Rejection
- Organ Transplant Market Size
- Antibodies In Development For Organ Transplant Rejection
- Bone Marrow And Stem Cell Transplantation/Graft-Versus-Host Disease
- Antibodies In Development For The Treatment Of Graft-Versus-Host Disease
- Rheumatoid Arthritis
- Antibodies In Development For The Treatment Of Rheumatoid Arthritis
- Other Therapeutic Applications
- Crohn’s Disease
- Psoriasis
- Rh Isoimmunity
- Antibodies In Development For Selection Other Diseases
- Diagnostic Imaging Applications
- In Vivo Diagnostic Imaging Antibody Products In Development For Selected Indications
- Disease/Indication
- Product/Antibody
- Company
- Development Status
- Colorectal Cancer (Surgical Treatment Of Metastatic Colorectal Cancer)
- Disease/Indication
- Product/Antibody
- Company
- Development Status
Industry Structure
- Originators
- Commercial Developers
- Vendors
- Manufacturers
- Technology Innovators
- The Regulatory Environment
- Market Share Of Monoclonal Antibody Product Manufacturers
- Genomics And Monoclonal Antibodies: A Match For Success
Company Profiles
- Abgenix, Inc.
- Business Overview
- Financial Information
- Leading Product Candidates
- Corporate Strategy
- Altarex Corporation
- Business Overview
- Financial Information
- Leading Product Candidates
- Celltech Group Plc
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Corixa Corporation
- Business Overview
- Financial Information
- Leading Product Candidates
- Corporate Strategy
- Cytogen Corporation
- Business Overview
- Financial Information
- Leading Products
- Genentech, Inc.
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Idec Pharmaceuticals Corporation
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Ilex Oncology Inc.
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Immunomedics, Inc.
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Medarex, Inc.
- Business Overview
- Financial Information
- Leading Product Candidates
- Corporate Strategy
- Medimmune, Inc.
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Millennium Pharmaceuticals, Inc.
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Nabi
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Protein Design Labs
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Protherics Plc
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
- Sangstat Medical Corporation
- Business Overview
- Financial Information
- Leading Products
- Xoma Ltd.
- Business Overview
- Financial Information
- Leading Products
- Corporate Strategy
Appendix: Company Names And Addresses
List Of Tables
Summary Table:
Worldwide Sales Of Therapeutic And Diagnostic Imaging Antibodies, Through 2007
1 Marketed Monoclonal Antibody Products And Their Sources
2 Worldwide Sales Of Monoclonal And Polyclonal Antibodies For Drugs And Diagnostics, Through 2007
3 Selected Therapeutic Monoclonal Antibodies: Worldwide Sales, Through 2007
4 Monoclonal Antibody Products On The Market
5 Monoclonal Antibody Products In Phase Iii Or Later Development
6 Range Of Egfr Expression In Solid Tumors
7 Egfr In Prognosis For Selected Tumor Types
8 Erbitux Clinical Trials
9 Selected Polyclonal Antibodies: Worldwide Sales, Through 2007
10 Polyclonal Antibody Products In Phase Iii Or Later Development A/0 May 2002
11 Diagnostic Imaging Antibodies: Worldwide Sales, Through 2007
12 Diagnostic Antibody Products In Phase Iii Or Later Development
13 Applications Of Selected Therapeutic Monoclonal Antibodies: Worldwide Sales, Through 2007
14 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Allergic Rhinitis And/Or Asthma
15 Incidence, Mortality, And Survival Rates For Common Cancers: U.S., 2002 (Estimated)
16 Cancer Prevalence Rates: U.S., 2000
17 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Specific Cancers
18 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Cardiovascular Diseases
19 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Infectious Diseases
20 U.S. Organ Transplants, 1992-1999
21 Therapeutic Antibody Products In Phase Ii Or Later Development For The Prevention Of Organ Transplant Rejection
22 Graft-Versus-Host Disease: Worldwide Incidence, 1998-2004
23 Therapeutic Antibody Products In Phase Ii Or Later Development For The Prevention Of Graft-Versus-Host Disease
24 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Rheumatoid Arthritis
25 Therapeutic Antibody Products In Phase Ii Or Later Development For The Treatment Of Selected Other Diseases
26 In Vivo Diagnostic Imaging Antibody Products In Phase Ii Or Later Development For Selected Indications
27 Abgenix’s Product Pipeline
28 Abgenix’s Corporate Partnerships
29 Celltech’s Product In Stage Ii Or Later Development
30 Corixa’s Product Pipeline
31 Cytogen’s Product Pipeline
32 Genentech’s Monoclonal Antibody Product Pipeline
33 Idec’s Product Pipeline
34 Idec’s Collaborative Arrangements
35 Immunomedics’ Product Pipeline
36 Medarex’s Product Pipeline
37 Medimmune’s Product Pipeline
38 Nabi’s Pharmaceutical Product Pipeline
39 Protherics’ Product Pipeline
List Of Figures
Summary Figure:
Worldwide Sales Of Therapeutic And Diagnostic Imaging Antibodies, 2001-2007
1 Applications Of Selected Therapeutic Monoclonal Antibodies: Worldwide Sales, Through 2007
2 Market Share Of Therapeutic Monoclonal Antibody
AbstractObjectives And Goals Of Study
The aim of this report is to provide a range of information-from detailed market analyses through industry trends-to quantify and qualify the emerging market for monoclonal and polyclonal antibody drugs. Forecasts and trends are gleaned from industry sources as well as from considered assessment of available and emerging technologies. The report develops forecasts for the pharmaceutical antibodies market for major disease applications from 2001 through 2007 and examines strategies employed by biotechnology companies and pharmaceutical firms to develop and market products in this explosive market sector.
Contribution Of The Study And For Whom
Antibody-based drugs, in particular monoclonal antibody-based products, began to enter the market in earnest in the late 1990s. After years of struggling with technical obstacles, products are emerging that are significantly changing the treatment of certain diseases. In 2002, antibodies were the single largest class of therapeutics in clinical development with the exception of vaccines. It is estimated that some 70 monoclonal antibody products were in clinical trials in 2002 and approximately 470 were estimated to be in development worldwide by some 200 companies. Essentially every biotech and pharmaceutical company, large or small, has a research program that centers on monoclonal antibodies.
The information and analysis presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.
Get Full Details About This Report >>
|
